Luis Felipe
Family Medicine · Hialeah, FLNPI 1649339730
Payments from drug & device makers
Across 144 payments — averaging $665.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82K
- Bristol Myers Squibb$12K
- Johnson & Johnson$274
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$216
- Lilly USA, LLC$197
- Boehringer Ingelheim$119
- plus $985 from 20 others
What the payments were for
- Food & beverage$2,397100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $82,065 |
| Bristol Myers Squibb | 2 | $11,974 |
| Johnson & Johnson | 15 | $274 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $216 |
| Lilly USA, LLC | 13 | $197 |
| Boehringer Ingelheim | 6 | $119 |
| Exact Sciences | 5 | $115 |
| Merck | 6 | $109 |
| Novo Nordisk | 5 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $99 |
| Novartis | 4 | $79 |
| Amarin Pharma, Inc. | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| AstraZeneca | 2 | $50 |
| Astellas Pharma US Inc | 1 | $47 |
| Pfizer | 2 | $44 |
| Bayer | 1 | $31 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Smith+Nephew | 1 | $27 |
| Eisai Inc. | 1 | $26 |
| Abbott | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Corium, LLC | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$95,830 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 293 | $221,083 |
| FarxigaDapagliflozin Propanediol | 193 | $129,029 |
| XareltoRivaroxaban | 129 | $104,362 |
| JardianceEmpagliflozin | 102 | $72,837 |
| EntrestoSacubitril/Valsartan | 61 | $52,396 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $47,116 |
| OzempicSemaglutide | 43 | $42,633 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 360 | $41,261 |
| JanuviaSitagliptin Phosphate | 61 | $39,585 |
| SynjardyEmpagliflozin/Metformin Hcl | 41 | $34,310 |
| TrulicityDulaglutide | 29 | $28,029 |
| SynthroidLevothyroxine Sodium | 262 | $25,854 |
| MyrbetriqMirabegron | 49 | $21,229 |
| BrilintaTicagrelor | 44 | $19,427 |
| Tadalafil | 88 | $18,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $44 | $228,259306 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Combivent Respimat, Tradjenta | $119 | $165,261226 claims |
| AstraZenecaFarxiga, Brilinta | $50 | $148,456237 claims |
| Johnson & JohnsonXarelto | $274 | $104,362129 claims |
| AbbVieSynthroid, Linzess, Namzaric, Lumigan | $82,065 | $55,912327 claims |
| NovartisEntresto | $79 | $52,39661 claims |
| MerckJanuvia, Janumet | $109 | $49,13672 claims |
| Novo NordiskOzempic | $101 | $42,63343 claims |
| Lilly USA, LLCTrulicity | $197 | $28,02929 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $21,22949 claims |
| Sanofi-aventis U.S. LLCMultaq | $99 | $10,20713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Hialeah
- Dario AltamiranoHialeah$15.5M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.